IRIS
CLERICO, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 35.029
EU - Europa 31.712
AS - Asia 7.311
SA - Sud America 778
Continente sconosciuto - Info sul continente non disponibili 202
AF - Africa 53
OC - Oceania 17
Totale 75.102
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 34.208
GB - Regno Unito 14.255
RU - Federazione Russa 5.879
UA - Ucraina 3.937
SG - Singapore 2.519
DE - Germania 2.297
IT - Italia 1.986
CN - Cina 1.566
VN - Vietnam 1.449
HK - Hong Kong 1.444
SE - Svezia 845
CA - Canada 793
DK - Danimarca 782
BR - Brasile 702
FI - Finlandia 639
PL - Polonia 535
FR - Francia 218
EU - Europa 202
IE - Irlanda 197
ID - Indonesia 62
KR - Corea 49
IN - India 48
NL - Olanda 40
RO - Romania 28
TR - Turchia 27
BD - Bangladesh 23
IQ - Iraq 21
AR - Argentina 19
EC - Ecuador 15
SK - Slovacchia (Repubblica Slovacca) 14
UZ - Uzbekistan 14
MX - Messico 13
PK - Pakistan 13
ZA - Sudafrica 13
AU - Australia 12
VE - Venezuela 12
AT - Austria 11
IL - Israele 11
MA - Marocco 11
IR - Iran 10
LT - Lituania 8
BE - Belgio 7
PY - Paraguay 7
TN - Tunisia 7
CL - Cile 6
CZ - Repubblica Ceca 6
JO - Giordania 6
JP - Giappone 6
KE - Kenya 6
CH - Svizzera 5
CO - Colombia 5
KZ - Kazakistan 5
NZ - Nuova Zelanda 5
PE - Perù 5
RS - Serbia 5
DZ - Algeria 4
HR - Croazia 4
TW - Taiwan 4
UY - Uruguay 4
AM - Armenia 3
AO - Angola 3
DO - Repubblica Dominicana 3
EG - Egitto 3
JM - Giamaica 3
LB - Libano 3
MY - Malesia 3
NG - Nigeria 3
NI - Nicaragua 3
NP - Nepal 3
OM - Oman 3
PS - Palestinian Territory 3
SA - Arabia Saudita 3
SM - San Marino 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
ES - Italia 2
GT - Guatemala 2
KH - Cambogia 2
LU - Lussemburgo 2
PA - Panama 2
SN - Senegal 2
SV - El Salvador 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
EE - Estonia 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
MD - Moldavia 1
MN - Mongolia 1
PH - Filippine 1
SR - Suriname 1
TH - Thailandia 1
Totale 75.102
Salva come PNG Salva come JPEG
Città #
Southend 12.638
Woodbridge 5.121
Ann Arbor 4.000
Chandler 3.260
Houston 2.984
San Mateo 2.512
Dearborn 1.956
Jacksonville 1.916
Falls Church 1.474
Hong Kong 1.366
Fairfield 1.187
Beijing 1.078
Seattle 1.037
Singapore 1.002
Cambridge 947
Dong Ket 828
Moscow 828
Wilmington 810
Stevenage 761
Portsmouth 692
Boardman 657
Lawrence 610
Warsaw 528
Ashburn 517
Pisa 462
Ottawa 456
Brooklyn 416
Montréal 195
Old Bridge 185
Dublin 184
Santa Clara 157
San Diego 136
Beauharnois 107
Redwood City 101
Norwalk 95
Milan 58
London 53
São Paulo 50
Rome 44
Munich 43
Chicago 39
Fremont 37
Los Angeles 33
Rio de Janeiro 32
Seoul 32
Central District 30
Augusta 29
Simi Valley 29
Hefei 27
Salerno 27
Helsinki 25
Washington 24
Bologna 23
Mountain View 23
Salt Lake City 22
Buffalo 21
Kansas City 21
Nanjing 21
Timisoara 20
Belo Horizonte 19
Kunming 19
Florence 18
Napoli 18
Pavia 18
Hanover 16
Jinan 16
Nuremberg 16
Trieste 15
Bratislava 14
Foggia 13
Guangzhou 13
Shanghai 13
Tashkent 13
Brasília 12
Islington 12
Shenzhen 12
Wayne 12
Frankfurt am Main 11
Fuzhou 11
Nanchang 11
Porto Alegre 11
Chiswick 10
Palermo 10
Baghdad 9
Curitiba 9
Leawood 9
Livorno 9
Lucca 9
Toronto 9
Verona 9
Council Bluffs 8
Fortaleza 8
Hebei 8
Paris 8
Potenza 8
Salvador 8
Sanayi 8
Tampa 8
West Jordan 8
Xian 8
Totale 52.442
Salva come PNG Salva come JPEG
Nome #
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 598
siRNA-mediated targeting of endothelial VWF prevents ET-1 upregulation in porcine aortic endothelial cells chronically exposed to angiotensin II 278
Downregulation of von Willebrand Factor prevents Ang II-induced endothelin-1 expression independently of eNOS activation in porcine endothelial cells 273
Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. 266
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 233
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 230
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 230
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 210
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. 206
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 198
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 195
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 195
State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study 194
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 191
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 187
Direct comparison of B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data 185
B-type natriuretic peptide secretion following scuba diving 184
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 184
Proposta per l’utilizzo in Pronto Soccorso delle troponine cardiache misurate con metodi di ultima generazione in pazienti con sospetto di sindrome coronarica acuta senza sopraslivellamento del tratto ST 183
Marcatori di rimodellamento e fibrosi cardiaca 178
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 176
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 175
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 173
Methodological assessment of mitochondrial respiratory chain-enzyme activities in cardiac tissue 172
No variation in Hsp70 mRNA level during cardiac surgery in pediatric patients evaluated by semiquantitative RT-PCR 171
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 171
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 170
125I-Endothelin-1 binding sites in human cardiac tissue 170
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 169
Valutazione esterna di qualità dei peptidi natriuretici BNP e NT-proBNP: risultati del programma Cardioormocheck 169
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 169
S-nitrosoglutathione as a substrate of gamma-glutamyltransferase (GGT)- A kinetic study 168
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 167
Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations 166
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 166
Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples 166
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 166
A sensitive and accurate plasma noradrenaline assay using a modified fluorimetric method. 165
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 165
Stato dell’arte dell’immunodosaggio dei peptidi natriuretici di tipo B 163
The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 162
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 162
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 162
Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients with Stable Angina 162
A chromatographic method for the determination of uric acid turnover in man 161
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 161
New and emerging biomarkers of heart failure 160
BNP values in the first days of life measured with an automated immunoassay platform 160
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 160
Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Reply Letter 159
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 159
Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco 159
Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty 158
Gamma-glumamyl-transferase levels are associated with inflammatory activation, myocardial dysfunction and mortality in pateints with ST-elevation myocardial infarction 157
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 156
Plasma gamma-glutamyltransferase fractions: diagnostic and prognostic predictive value 156
New biomarkers for risk stratifications in patients with heart failure: high-sensitivity troponin I and galectin-3 156
Natriuretic peptide testing in primary care patients. 155
A chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using quality control sera assayed in an interlaboratory survey 155
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 155
Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. 154
Genomic medicine and thrombotic risk: who, when, how and why? 154
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 154
Heat shock protein 70-1 gene expression in pediatric heart surgery using blood cardioplegia. 153
Clinical relevance of time course of BNP levels in neonates with congenital heart diseases 152
Ultrafiltration: a rational treatment for heart failure. 151
A new immunoradiometric assay for the measurement of N-terminal fragment of proatrial natriuretic peptide in human plasma: relationship with atrial and brain natriuretic peptides 151
Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients 150
Plasma levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and N-terminal fragment of pro-ANP in heart failure and in controls 150
Comparison of two BNP immunoassays using the same antibodies and standard materials 150
Reference values for urinary neutrophil gelatinase-associated lipocalin (NGAL) in pediatric age measured with a fully automated chemiluminescent platform 150
Cardiac biomarker testing in the clinical laboratory:Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 150
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences 150
Circulating levels of cardiac natriuretic peptides measured by highly sensitive and specific IRMA methods in normal subjects and in patients with heart failure 149
The non-thyroidal illness syndrome after coronary artery bypass grafting: a 6-month follow-up study. 148
C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. 148
Methodological and clinical evaluation of the Liaison automated analyser for the qunatitative detrmination of 25-OH-vitamin D. 148
Evaluation of analytical performance and qualità specifications of a novel immunoenzymometric assay for cTnI: comparison with cTnI and cTnT immunoassays 148
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: compariosn with the old method and the Access system 147
Evaluation of Analytical Performance of the Siemens ADVIA TnI Ultra Immunoassay 147
Determinazione dei siti di legame dell’endotelina su membrane di atrio e di ventricolo bovino: un modello per studi di legame du tessuto cardioaco umano 147
Analytical and clinical preformance of NT-proBNP immunoassay 147
Cardiac Natriuretic Hormones, Neuro-Hormones, Thyroid Hormones and Cytokines in Normal Subjects and Patients with Heart Failure. 146
Diagnostic, prognostic and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases 146
B-type plasma natriuretic hormone level in operated Fallot patients 146
Gamma-glutamyltransferase levels are associated with inflammatory activation, myocardial dysfunction and in-hospital mortality in patients with ST-elevation myocardial infarction 146
Clinical relevance of biological variation: the lesson of brain natriuretic peptide (BNP) and NT-proBNP assay. 145
Multicentre comparison of free thyroid hormones immunoassays: the Immunocheck study 145
Immunoradiometric assay of serum myosin as a marker of myocardial cell damage: methodological and clinical evaluation 145
Abnormal circulating levels of muscle enzymes and myoglobin in hypothyroidism: their significance and usefulness in follow-up of replacement therapy of the metabolic disorder 145
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 145
Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation 145
Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review 144
When gonads talk to the heart sex hormones and cardiac endocrine function. 144
ANP tissue extraction is not changed by large icrease of its plasma levels induced by pacing 144
State of the Art of Immunoassay Methods for B-Type Natriuretic Peptides: an Update 143
Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. 143
Distribution of plasma cardiac troponin I values in healthy subjects: pathophysiological considerations. 143
Plasmatic levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 143
When the heart is burning: Amino-terminal pro-brain natriuretic peptide as an early marker of cardiac involvement in active autoimmune rheumatic disease 142
Totale 17.048
Salva come PNG Salva come JPEG
Categoria #
all - tutte 364.415
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 364.415
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.515 0 0 0 0 0 0 0 0 0 108 95 1.312
2020/202111.162 332 1.907 734 473 770 1.690 1.093 324 741 382 1.035 1.681
2021/20228.252 276 1.896 208 966 62 55 887 1.779 511 924 56 632
2022/20236.603 616 117 70 1.176 1.151 1.248 12 531 1.101 143 267 171
2023/20241.761 370 85 290 104 72 276 232 72 25 47 29 159
2024/202512.328 116 65 1.084 346 275 1.163 2.348 5.046 1.570 315 0 0
Totale 75.327